EASTERN COOPERATIVE ONCOLOGY GROUP

约翰斯·霍普金斯自1955年以来一直是ECOG的成员。我们的主要目标是将约翰·霍普金斯大学试点的创新临床研究方案和实验室相关研究带到ECOG进一步发展。与此相结合，我们作为礼仪研究主席、面向疾病和模式的委员会主席以及委员会成员层面的广泛参与提供领导。在这次拨款更新期间的具体目标是：(1)继续在以疾病为导向的委员会中提供科学领导，这些委员会包括：肺、头颈、乳房、病理、脑肿瘤、艾滋病、恶性肿瘤，并将这些努力扩大到骨髓瘤、白血病、淋巴瘤和骨髓瘤。(2)将转化研究、细胞生物学和分子生物学纳入包括预防在内的所有疾病阶段的临床方案；(3)扩大我们的收益；(4)增加我们附属社区医院的参与。我们希望通过我们教员的成功努力，获得实验室科学和临床研究的资助，如肺癌、前列腺癌和胰腺癌的孢子资助，以及我们与NCI持续的第一阶段合同，从而实现这些目标。这些赠款将用于开发第一阶段临床试验，包括一项骨髓移植、基因疗法和新型细胞毒剂，约翰霍普金斯大学随后可以将这些药物带到ECOG进行针对疾病的第二阶段和第三阶段评估。约翰霍普金斯大学参与ECOG的新领域包括泌尿生殖系统和血液系统恶性肿瘤。建立了将这两个领域的创新研究项目纳入经社理事会的机制。随着我们计划在约翰·霍普金斯大学建立一个新的更大的癌症中心，由于临床项目和教师的扩大，预计应计收入将增加。此外，还任命了一名新的地区项目主任，其具体目标是扩大我们的医院网络，以便更多地获得ECOG/NCI赞助的高度优先的试验，包括癌症控制和预防研究。

Johns Hopkins has been a member of ECOG since 1955. Our primary goal is to bring innovative clinic research protocols and laboratory correlative studies piloted at Johns Hopkins to ECOG for further development. In conjunction with this, we provide leadership as protocol study chairs, disease and modality oriented committee chairs, as well as wide committee participation at the membership level. The specific aims during this grant renewal period are to: (1) continue to provide scientific leadership in the disease oriented committees: Lung, Head and Neck, Breast, Pathology, Brain Tumors, AIDS malignancies and to expand these efforts into GU, leukemia, lymphoma and myeloma. (2) to bring translational research, cell biology and molecular biology into clinical protocols for all stages of disease including prevention; (3) to expand our accrual; (4) to increase participation of our affiliated community hospitals. We expect to achieve these aims through the successful efforts of our faculty in obtaining funded laboratory science and clinical research grants such as the SPORE grants in lung, prostate and pancreatic cancer and our continuing Phase I Contract with the NCI. These grants will allow the development of phase I clinical trials including one marrow transplantation, gene therapies, and novel cytotoxic agents, with Johns Hopkins that can then be taken to ECOG for disease-specific phase II and phase III evaluation. New areas of Johns Hopkins involvement in ECOG include genitourinary and hematologic malignancies. Mechanisms are in place to bring innovative research projects in these 2 areas into ECOG. Accrual is expected to increased because of expanded clinical programs and faculty as we plan for a new larger Cancer Center at Johns Hopkins. In addition, a new director of Regional Programs has been appointed with the specific goal of expanding our hospital network to provide greater access to high priority ECOG/NCI sponsored trials including cancer control and prevention studies.